<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561548</url>
  </required_header>
  <id_info>
    <org_study_id>06 - PP - 2006</org_study_id>
    <secondary_id>2006-006877-26</secondary_id>
    <nct_id>NCT00561548</nct_id>
  </id_info>
  <brief_title>Impact of Anti-Tumor Necrosis Factor (TNF) Antibodies on the T-lymphocyte and Macrophage Cooperation in Crohn Disease</brief_title>
  <official_title>Impact of Anti-TNF Antibodies on the T-lymphocyte and Macrophage Cooperation in the Crohn Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research is to study Crohn disease patients before and after anti-TNF, the
      cooperation between lamina propria T-lymphocytes and macrophages, through the expression of
      co-signalisation molecules and their ligands, the production of cytokines participating in
      this cooperation, and the potential role of regulatory T lymphocytes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Crohn disease is an inflammatory disease and its frequency has been increasing over the last
      25 years. The physiopathology involves a failure in the negative regulatory mechanisms of the
      inflammatory responses in the intestines, along with an excessive production of TNF-α by
      T-lymphocytes and macrophages of the lamina propria.

      Anti-TNF-α antibodies usually give good therapeutic results, in particular in patients who
      are resistent or dependant on steroids. Nevertheless, in Crohn disease, the destructive
      T-lymphocytes - macrophage interactions, their inhibition by anti-TNFα, and the impact of
      these antibodies on cellular signaling remain largely unknown.

      Two groups of 10 patients with active Crohn disease, with or without azathioprine, and
      requiring the start of anti-TNF treatment are included in this study. Rectosigmoïdal biopsies
      and blood tests will be done before starting the treatment and after 10 weeks of treatment.
      Surface antigens, cytokines and cellular molecules and the number of apoptotic cells will be
      analyzed by FACS, and the quantification of RNA will be analyzed by RT-PCR.

      This will therefore enable us to study, before and after anti-TNF-α, in patients treated or
      not with azathioprine, on intestinal and blood lymphocytes, the production of cytokines
      involved in the lymphocyte-macrophage interaction, and the potential role of regulatory T
      cells.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative variation (%) in apoptotic cells calculated according to the formula: (% of induced apoptotic cells) - (% of spontaneous apoptotic cells)</measure>
    <time_frame>before treatment and 10 weeks after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte activation markers and macrophage activation markers</measure>
    <time_frame>before treatment and 10 weeks after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with active Crohn disease and with azathioprine treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with active crohn disease and without azathioprine disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>rectosigmoïdal biopsies</intervention_name>
    <description>rectosigmoïdal biopsies</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient older than 18

          -  social security

          -  active Crohn disease defined by a CDAI &gt; 250

          -  sigmoïdal and/or rectal lesions

          -  requiring treatment by infliximab

          -  having never received any anti-TNF treatment

          -  a negative pregnancy test for women

          -  prescription of efficient contraception for women, having started at least a month
             before beginning the study, and throughout the duration of the study

          -  acceptance to participate in this research and having signed the consent form

          -  not participating in any other study

        Exclusion Criteria:

          -  consent withdrawal

          -  the halt of infliximab treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Hébuterne, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fédération des Maladies de l'appareil Digestif et de la Nutrition</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Puntis J, McNeish AS, Allan RN. Long term prognosis of Crohn's disease with onset in childhood and adolescence. Gut. 1984 Apr;25(4):329-36.</citation>
    <PMID>6706211</PMID>
  </reference>
  <reference>
    <citation>Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther. 2000 Dec;14(12):1553-9.</citation>
    <PMID>11121902</PMID>
  </reference>
  <reference>
    <citation>Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res. 2003 Jan;47(1):1-10. Review.</citation>
    <PMID>12526855</PMID>
  </reference>
  <reference>
    <citation>ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002 Feb;50(2):206-11.</citation>
    <PMID>11788561</PMID>
  </reference>
  <reference>
    <citation>MacDonald TT, Di Sabatino A, Gordon JN. Immunopathogenesis of Crohn's disease. JPEN J Parenter Enteral Nutr. 2005 Jul-Aug;29(4 Suppl):S118-24; discussion S124-5, S184-8. Review. Erratum in: JPEN J Parenter Enteral Nutr. 2006 Jan-Feb;30(1):table of contents. DiSabatino, Antonio [corrected to Di Sabatino, Antonio].</citation>
    <PMID>15980273</PMID>
  </reference>
  <reference>
    <citation>Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994 Oct;1(7):553-62.</citation>
    <PMID>7600284</PMID>
  </reference>
  <reference>
    <citation>Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut. 1998 Aug;43(2):203-9.</citation>
    <PMID>10189845</PMID>
  </reference>
  <reference>
    <citation>Itoh J, de La Motte C, Strong SA, Levine AD, Fiocchi C. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut. 2001 Jul;49(1):35-41.</citation>
    <PMID>11413108</PMID>
  </reference>
  <reference>
    <citation>Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 1999 Jan;116(1):22-8.</citation>
    <PMID>9869598</PMID>
  </reference>
  <reference>
    <citation>Filippi J, Mambrini P, Arab K, Schneider SM, Hébuterne X. [Treatment of oesophageal Crohn's disease by infliximab]. Gastroenterol Clin Biol. 2005 Jan;29(1):84-5. French.</citation>
    <PMID>15738903</PMID>
  </reference>
  <reference>
    <citation>Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology. 2005 Feb;128(2):376-92.</citation>
    <PMID>15685549</PMID>
  </reference>
  <reference>
    <citation>Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine. 2001 Aug 21;15(4):212-22.</citation>
    <PMID>11563881</PMID>
  </reference>
  <reference>
    <citation>Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001 Nov;121(5):1145-57.</citation>
    <PMID>11677207</PMID>
  </reference>
  <reference>
    <citation>Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Piqué JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol. 2006 Feb 15;176(4):2617-24.</citation>
    <PMID>16456024</PMID>
  </reference>
  <reference>
    <citation>Filippi J, Roger PM, Schneider SM, Durant J, Breittmayer JP, Benzaken S, Bernard A, Dellamonica P, Hébuterne X; Groupe d'Etude Niçois Polyvalent en Infectiologie (GENPI). Infliximab and human immunodeficiency virus infection: Viral load reduction and CD4+ T-cell loss related to apoptosis. Arch Intern Med. 2006 Sep 18;166(16):1783-4.</citation>
    <PMID>16983059</PMID>
  </reference>
  <reference>
    <citation>Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, Nakamura T, Koganei K, Fukushima T, Watanabe M. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol. 2004 Sep 1;173(5):3119-30.</citation>
    <PMID>15322172</PMID>
  </reference>
  <reference>
    <citation>Kelsen J, Agnholt J, Hoffmann HJ, Rømer JL, Hvas CL, Dahlerup JF. FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease. Clin Exp Immunol. 2005 Sep;141(3):549-57.</citation>
    <PMID>16045746</PMID>
  </reference>
  <reference>
    <citation>Ochsenkühn T, Göke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease. Am J Gastroenterol. 2002 Aug;97(8):2022-5.</citation>
    <PMID>12190171</PMID>
  </reference>
  <reference>
    <citation>Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004 May;126(6):1593-610. Review.</citation>
    <PMID>15168370</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>November 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <last_update_submitted>May 27, 2011</last_update_submitted>
  <last_update_submitted_qc>May 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Département de la Recherche Clinique et de l'Innovation</name_title>
    <organization>CHU de Nice</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

